Free Trial

Medexus Pharmaceuticals Q1 2024 Earnings Report

Medexus Pharmaceuticals logo
C$2.82 +0.22 (+8.46%)
(As of 12/20/2024 05:17 PM ET)

Medexus Pharmaceuticals EPS Results

Actual EPS
C$0.04
Consensus EPS
-C$0.03
Beat/Miss
Beat by +C$0.07
One Year Ago EPS
N/A

Medexus Pharmaceuticals Revenue Results

Actual Revenue
$42.39 million
Expected Revenue
$39.98 million
Beat/Miss
Beat by +$2.41 million
YoY Revenue Growth
N/A

Medexus Pharmaceuticals Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Medexus Pharmaceuticals Earnings Headlines

Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
See More Medexus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medexus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medexus Pharmaceuticals and other key companies, straight to your email.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals (TSE:MDP) operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.

View Medexus Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings